Measure eight essential components of CAR-T biology with 780 human genes. Ideally suited for new CAR-T development and QC, the CAR-T Characterization Gene Expression Panel can help streamline the CAR-T manufacturing workflow and potentially reduce vein to vein time. Confidently profile CAR-T products for research and manufacturing applications with a robust, automated, and reproducible assay. Empower your knowledge of CAR-T with the most up-to-date biology developed with experts in the field.
- Optimize CAR-T method development
- Create manufacturing acceptance criteria
- Measure metabolic fitness and persistence
- Monitor post-infusion exhaustion and toxicity
CAR-T Therapy Workflow
Understanding each step of the CAR-T workflow is critical to ensuring quality and efficacy of the final CAR-T product. The nCounter CAR-T Characterization Panel can be used throughout development and manufacturing as a standardized panel of genes for optimizing methods, developing manufacturing acceptance criteria as well as understanding the host influences beyond manufacturing.
In addition to the standard nSolver™ Analysis, genes included in the CAR-T Characterization panel are organized and linked to various advanced analysis modules to allow for efficient exploration of the eight essential aspects of CAR-T biology.
Advanced Analysis Modules available for CAR-T Characterization:
- TCR Diversity Score (coming soon)
- Quality Control
- Pathway Analysis
- Cell Profiling
- Differential Expression
- Gene Set Analysis
- Built-in compatibility for Panel-Plus and Protein analysis
|Essential CAR-T Biology||Description||Pathways and Processes|
|Phenotype||Multiple subtypes of T-cells and the phenotypic changes that accompany them can be distinguished via the cytokines and pathways that maintain, promote, and modulate their activity.||Notch, Wnt signaling, Tfh, TGF-beta, Th1, Th17, Th2, Th9, Treg, Innate-like T-cells, Vitamin A (RA) Signaling|
|Cell Types||Other cell types can contaminate the population of active CAR-T cells. Similarly, measurement of B-cell populations may aid in assessment of whole blood post-infusion measurement of tumor burden in B-cell lymphomas.||Immune cell profiling|
|TCR Diversity||The TCR diversity of CAR-T cells can provide information on the number of clones present after leukapheresis, manufacturing, and infusion.||TCR Content|
|Activation||T-cell activation is primarily mediated by antigens presented to the TCR complex and modulated by costimulatory molecules. Downstream of the TCR, multiple pathways induce transcriptional changes that lead to the production of chemokines and cytokines. Cell surface receptors signal a change in phenotype.||Chemokine Signaling, Costimulatory Molecules, Interleukin Signaling, TCR signaling, JAK-STAT, MAPK and PI3K Signaling, Myc targets, NFAT, Antigen processing & presentation, T-cell activation markers|
|Metabolism||Fundamental changes in T-cell metabolism are induced upon activation to enable rapid cell division and thus expansion of relevant clones. These changes can be observed across basic metabolic pathways, including carbohydrate and fatty acid metabolism.||
Glycolysis, Mitochondrial biogenesis, Fatty Acid MetabolismGlutamine metabolism, Circadian Clock, One-carbon metabolism, Oxidative phosphorylation, mTOR, Cell Cycle, Autophagy
|Persistence||Ongoing presence of a T-cell and cytotoxic T-cell population can be measured by via cell type profiling. By measuring molecules involved in T-cell migration we can assess the ability of T-cells to home in on their target antigens.||T-cell migration, T-cell cell type profiling|
|Exhaustion||T-cell exhaustion can be induced by costimulatory molecules, other cell-cell interactions, and cell death via apoptosis.||T-cell exhaustion markers, Apoptosis, Interactions with Non-Lymphoid Cells, Costimulatory Molecules|
|Toxicity||Toxicity is correlated with certain cytokine and chemokine profiles. These signals can induce a pro-inflammatory environment in various tissues and lead to off-target toxicities of CAR-T treatment.||
NK cell cytotoxicity, NKT Receptors, NF-kB, Type I interferon signalingType II interferon signaling, Interleukin signaling, Chemokine signaling
|Chain Type||Constant Chains||Variable Chains|
|Immune Cell Markers|
CD3D/E/G, CD4, CD8A/B, PTPRC (CD45), CD45R0, CD45RA, SELL (CD62L), CCR7, CD28, CD40LG, IL2RA (CD25), NCR1 (NKp46)
|Cell Type||Description||Panel Genes|
|B Cells||B cells are the primary mediators of the humoral immune response, bearing antigen-specific B cell receptors and producing antibodies that can enable the immune system to respond to a broad variety of antigens. B cells can also function as MHC class II antigen presenting cells to stimulate T cell immunity.||BLK, CD19, CD20, TNFRSF17|
|T Cells||T-cells mediate cell-based immunity by recognizing primarily peptide antigens displayed on MHC class I or class II and either producing cytokines or directly killing the presenting cell.||CD3D, CD3E, CD3G, CD6, SH2D1A|
|TH1||CD4+ T cell subset that produces IL2 and Interferon-gamma to promote cellular immunity by acting on CD8+ T Cells, NK Cells and Macrophages.||TBX21|
|Regulatory T Cells (Tregs)||CD4+ T Cells that suppress effector B and T Cells and play a central role in suppression of the immune response and tolerance to self-antigens.||FOXP3|
|CD8+ T Cells||A subset of T cells that are capable of binding cognate-antigen expressing cells via class I MHC and directly lysing them via perforin and granzymes.||CD8A, CD8B|
|Exhausted CD8+ T Cells||T-cells overstimulated by antigen can develop an "exhausted" phenotype, in which they are no longer effective in targeting antigen-bearing cells.||CD244, EOMES, CD223|
|Cytotoxic Cells||All cells capable of cytotoxic activity, which can include T, NKT, and NK-cells.||CTSW, GNLY, GZMA, GZMB, GZMH, CD161, CD94, KLRK1, PRF1|
|Dendritic Cells||Professional antigen presenting cells that internalize, process, and present antigens to lymphocytes via MHC class I and class II along with costimulatory signals to initiate cellular immune responses.||CCL13, CD209, HSD11B1|
|Macrophages||Pluripotent cells with critical roles in initiating innate and adaptive immune responses, phagocytosing abnormal cells, and regulating wound healing and tissue repair.||CD163, CD68, CD84|
|Mast Cells||Mast cells release histamine containing granules and other signals in order to promote inflammation and regulate allergic responses.||MS4A2, TPSAB1|
|Neutrophils||Neutrophils are highly abundant cells that respond early to sites of infection or inflammation, phagocytose cellular debris, and promote downstream immunity.||CSF3R, CD16, S100A12|
|Natural Killer (NK) Cells||Cytotoxic cells of the innate immune system that are a significant source of interferon-gamma and are capable of directly killing targeted cells via detection of a loss in MHC surface expression.||NKP46, XCL2|
|NK CD56dim cells||The amount of CD56 present on an NK cell is indicative of its age and differentiation state; CD56 dim cells are mature NK cells, more commonly found in peripheral blood than secondary lymphoid tissues, and have the greatest cytolytic activity.||IL21R, KIR2DL3, KIR3DL1, KIR3DL2|
|Number of Targets||780 (Human), including internal reference genes|
|Sample Input - Standard (No amplification required)||25-300 ng|
|Sample Input - Low Input||As little as 1 ng with nCounter Low Input Kit (sold separately)|
|Sample Type(s)||PBMC, FFPE-derived RNA, total RNA, fragmented RNA, cell lysate, sorted cells, whole blood/plasma, synovial fluid|
|Customizable||Add up to 30 unique genes with Panel-Plus and up to 10 custom protein targets|
|Time to Results||Approximately 24 hours|
|Data Analysis||nSolver™ Analysis Software (RUO)|
Click here to view publications on CAR-T
Selected Panel References:
- Fraietta, JA et al. Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted Cells. Nature. 2018;558(7709):307-12.
- Fraietta JA et al. Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy of Chronic Lymphocytic Leukemia. Nature Medicine. 2018;24(5):563-71.
- Raud B et al. Fatty Acid Metabolism in CD8+ T Cell Memory: Challenging Current Concepts. Immunological Reviews. 2018;283(1):213-31.
- Vargas TR and Apetoh L. The Secrets of T Cell Polarization. In: Zitvogel L and Kroemer G. (eds) Oncoimmunology. 2018:69-95.
- Xiao, X et al. Mucosal-Associated Invariant T Cells: New Insights into Antigen Recognition and Activation. Frontiers in Immunology. 2017;8:1540.
- Simone MD et al. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor Infiltrating T Regulatory Cells. Immunity. 2016;45(5):1135-47.
- Buck, MD et al. T Cell Metabolism Drives Immunity. Journal of Experimental Medicine. 2015;212;(9):1345-60.
- Eberl G et al. Innate Lymphoid Cells: A New Paradigm in Immunology. Science. 2015;348(6237).
- Best JA et al. Transcriptional Insights into the CD8+ T Cell Response to Infection and Memory T Cell Formation. Nature Immunology. 2013;14(4):404-12.
- Chtanova T et al. Identification of T Cell-Restricted Genes, and Signatures for Different T Cell Responses, Using a Comprehensive Collection of Microarray Datasets. Journal of Immunology. 2005;175(12):7837-47.
|Product||Product Description||Quantity||Catalog Number|
|nCounter Human CAR-T Characterization Panel||Includes 780 genes;10 internal reference genes for data normalization||12 Reactions||XT-CSO-CART1-12|
|nCounter Human PanCancer IO 360 + Panel Standard||Includes 770 genes; 20 internal reference genes for data normalization. Panel standard includes a pool of synthetic oligonucleotides that correspond to the target sequences in the panel||12 Reactions||XT-CSPS-HIO360-12|
|nCounter Human PanCancer Immune Profiling Panel||Includes 770 genes; 40 internal reference genes for data normalization||12 Reactions||XT-CSO-HIP1-12|
NanoString is excited to be working with Servier (as project leader), Bayer, Janssen, and Takeda as partners with the Innovative Medicines Initiative (IMI) Consortium in the European Union to develop gold standard analytical methods to use throughout development, manufacturing, and delivery of CAR-T cell therapies. The IMI is the largest public-private partnership in the world dedicated to health research.
Researchers interested in participating in this project are encouraged to attend a series of upcoming webinars outlining the IMI rules and procedures, the opportunity for small and medium-sized enterprises, and the specific project deliverables on June 18th, 20th, and 25th, respectively.
Webinar #1: IMI Rules and Procedures
- June 18th, 11:00 CEST
Webinar #2: Opportunities for Small and Medium Sized Enterprises in IMI2 – Call 18
- June 20th, 11:00 CEST
Webinar #3: Supporting the Development of CAR-T Cells
- June 25th, 11:00 CEST
For Research Use Only. Not for use in diagnostic procedures.